Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down prior to trading on Monday . The stock had previously closed at $29.16, but opened at $27.49. Chugai Pharmaceutical shares last traded at $28.88, with a volume of 34,048 shares trading hands.

Wall Street Analyst Weigh In

CHGCY has been the topic of several recent research reports. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, Chugai Pharmaceutical has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Down 1.0%

The firm has a market capitalization of $95.01 billion, a PE ratio of 33.18 and a beta of 0.60. The business has a 50-day moving average price of $29.08 and a 200-day moving average price of $26.11.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The firm had revenue of $2.25 billion for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%. On average, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.